Legend Biotech Statistics
Total Valuation
Legend Biotech has a market cap or net worth of $5.34 billion. The enterprise value is $4.69 billion.
Important Dates
The last earnings date was Tuesday, May 13, 2025, before market open.
Earnings Date | May 13, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Legend Biotech has 184.29 million shares outstanding. The number of shares has increased by 1.67% in one year.
Current Share Class | n/a |
Shares Outstanding | 184.29M |
Shares Change (YoY) | +1.67% |
Shares Change (QoQ) | -8.76% |
Owned by Insiders (%) | 0.14% |
Owned by Institutions (%) | 48.02% |
Float | 81.63M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 7.29 |
Forward PS | n/a |
PB Ratio | 5.23 |
P/TBV Ratio | 5.25 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 6.44 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.20, with a Debt / Equity ratio of 0.36.
Current Ratio | 5.20 |
Quick Ratio | 5.00 |
Debt / Equity | 0.36 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -11.22 |
Financial Efficiency
Return on equity (ROE) is -20.00% and return on invested capital (ROIC) is -10.33%.
Return on Equity (ROE) | -20.00% |
Return on Assets (ROA) | -8.77% |
Return on Invested Capital (ROIC) | -10.33% |
Return on Capital Employed (ROCE) | -17.23% |
Revenue Per Employee | $279,150 |
Profits Per Employee | -$83,614 |
Employee Count | 2,609 |
Asset Turnover | 0.43 |
Inventory Turnover | 25.08 |
Taxes
In the past 12 months, Legend Biotech has paid $20.67 million in taxes.
Income Tax | 20.67M |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -32.43% in the last 52 weeks. The beta is 0.20, so Legend Biotech's price volatility has been lower than the market average.
Beta (5Y) | 0.20 |
52-Week Price Change | -32.43% |
50-Day Moving Average | 32.21 |
200-Day Moving Average | 39.61 |
Relative Strength Index (RSI) | 39.52 |
Average Volume (20 Days) | 1,774,584 |
Short Selling Information
Short Interest | 7.58M |
Short Previous Month | 6.74M |
Short % of Shares Out | 7.90% |
Short % of Float | n/a |
Short Ratio (days to cover) | 4.32 |
Income Statement
In the last 12 months, Legend Biotech had revenue of $728.30 million and -$218.15 million in losses. Loss per share was -$1.19.
Revenue | 728.30M |
Gross Profit | 62.61M |
Operating Income | -237.93M |
Pretax Income | -287.07M |
Net Income | -218.15M |
EBITDA | -228.34M |
EBIT | -237.93M |
Loss Per Share | -$1.19 |
Full Income Statement Balance Sheet
The company has $1.01 billion in cash and $362.81 million in debt, giving a net cash position of $642.57 million or $3.49 per share.
Cash & Cash Equivalents | 1.01B |
Total Debt | 362.81M |
Net Cash | 642.57M |
Net Cash Per Share | $3.49 |
Equity (Book Value) | 1.02B |
Book Value Per Share | 5.53 |
Working Capital | 984.42M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$263.31 million and capital expenditures -$9.86 million, giving a free cash flow of -$273.17 million.
Operating Cash Flow | -263.31M |
Capital Expenditures | -9.86M |
Free Cash Flow | -273.17M |
FCF Per Share | -$1.48 |
Full Cash Flow Statement Margins
Gross margin is 8.60%, with operating and profit margins of -32.67% and -29.95%.
Gross Margin | 8.60% |
Operating Margin | -32.67% |
Pretax Margin | -27.11% |
Profit Margin | -29.95% |
EBITDA Margin | -31.35% |
EBIT Margin | -32.67% |
FCF Margin | n/a |
Dividends & Yields
Legend Biotech does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -1.67% |
Shareholder Yield | -1.67% |
Earnings Yield | -4.09% |
FCF Yield | -5.12% |
Dividend Details Analyst Forecast
The average price target for Legend Biotech is $77.09, which is 166.29% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $77.09 |
Price Target Difference | 166.29% |
Analyst Consensus | Strong Buy |
Analyst Count | 12 |
Revenue Growth Forecast (5Y) | 36.93% |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Legend Biotech has an Altman Z-Score of 7.3 and a Piotroski F-Score of 2.
Altman Z-Score | 7.3 |
Piotroski F-Score | 2 |